Some hopes and concerns regarding medical event-reporting systems - Lessons from the NASA Aviation Safety Reporting System

被引：0
|
作者：
Billings, CE [1 ]
机构：
[1] Ohio State Univ, Cognit Syst Engn Lab, Columbus, OH 43210 USA
来源：
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE | 1998年 / 122卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [21] Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system
    Ding, Yiling
    Su, Hongyan
    Shu, Yamin
    Chen, Jing
    HELIYON, 2024, 10 (09)
  • [22] Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System
    Ball, R
    Braun, MM
    Mootrey, GT
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) : 1273 - 1280
  • [23] Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Xiaoxuan Xing
    Xiaotong Zhang
    Ke Wang
    Zhizhou Wang
    Yingnan Feng
    Xiaoxi Li
    Yiming Hua
    Lan Zhang
    Xianzhe Dong
    Alzheimer's Research & Therapy, 17 (1)
  • [24] Alarms, alerts, and warnings in air traffic control: An analysis of reports from the Aviation Safety Reporting System
    Ruskin, Keith J.
    Corvin, Chase
    Rice, Stephen
    Richards, Grace
    Winter, Scott R.
    Ruskin, Anna Clebone
    TRANSPORTATION RESEARCH INTERDISCIPLINARY PERSPECTIVES, 2021, 12
  • [25] Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
    Bai, Yang
    Wu, Bin
    Gou, Liangwen
    Fang, Zhenwei
    Xu, Ting
    Zhang, Tiejun
    Li, Yuwen
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [26] Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
    Zhu, Zhou
    Liu, Mingjuan
    Zhang, Hanlin
    Zheng, Heyi
    Li, Jun
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [27] Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
    Zhuang, Wei
    Xu, Jiabing
    Wu, Ye
    Yang, Jianhui
    Lin, Xiuxian
    Liao, Yufang
    Wan, Jun
    Weng, Lizhu
    Lin, Wanlong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (09) : 2830 - 2842
  • [28] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Zhao, Dan
    Zhang, Wangxin
    Liu, Yan
    Yan, Zhaojun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
    Gastaldon, Chiara
    Raschi, Emanuel
    Kane, John M.
    Barbui, Corrado
    Schoretsanitis, Georgios
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 90 (01) : 41 - 48
  • [30] Comparative Safety of Dimethyl Fumarate and Fingolimod: Findings from the FDA Adverse Event Reporting System (FAERS)
    Roman, Cortnee
    Hersh, Carrie
    Sillau, Stefan
    Alvarez, Enrique
    NEUROLOGY, 2021, 96 (15)
12345